Tadalafil (Cialis / Adcirca): The Complete Guide

Overview

Tadalafil was developed by the pharmaceutical partnership of ICOS Corporation and Eli Lilly and Company. It received its first FDA approval in November 2003 under the brand name Cialis for the treatment of erectile dysfunction, entering a market already established by sildenafil (Viagra, approved 1998) and vardenafil (Levitra, approved 2003). Despite being the third PDE5 inhibitor to market, tadalafil quickly differentiated itself through its markedly longer duration of action — up to 36 hours compared to 4–6 hours for sildenafil and vardenafil (Brock et al., 2002).

The mechanism of action is shared across the PDE5 inhibitor class: tadalafil inhibits phosphodiesterase type 5, an enzyme that degrades cyclic guanosine monophosphate (cGMP) in smooth muscle cells. By preventing cGMP breakdown, tadalafil prolongs and amplifies the smooth muscle relaxation and vasodilation initiated by nitric oxide (NO) signaling. In the penis, this translates to increased blood flow to the corpus cavernosum and improved erectile function. In the pulmonary vasculature, it reduces pulmonary arterial pressure. In the prostate and bladder neck, it relaxes smooth muscle to relieve urinary symptoms (Forgue et al., 2006).

What sets tadalafil apart pharmacologically is its selectivity profile and pharmacokinetics. It has minimal activity against PDE6 (the retinal enzyme responsible for the visual disturbances seen with sildenafil) and notably greater selectivity for PDE11, though the clinical significance of PDE11 inhibition remains debated. Its 17.5-hour half-life — roughly 4–5 times longer than sildenafil's — is the result of its unique chemical structure (a methylenedioxyphenyl group), which slows hepatic metabolism via CYP3A4 (Forgue et al., 2006).

The daily low-dose formulation (2.5–5 mg), approved by the FDA in 2008 for ED and in 2011 for BPH/LUTS, represented a paradigm shift in PDE5 inhibitor therapy. Rather than taking a pill 30–60 minutes before sexual activity, men could take a daily tablet that maintained steady-state plasma concentrations sufficient for erectile response at any time. This approach eliminated the need for anticipation and planning, which many patients and partners found psychologically burdensome (Porst et al., 2006).

In 2009, tadalafil received a separate FDA approval under the brand name Adcirca (40 mg once daily) for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability. The PAH approval was based on the PHIRST trial (Pulmonary Arterial Hypertension and Response to Tadalafil), which demonstrated significant improvement in six-minute walk distance and delayed time to clinical worsening (Galiè et al., 2009).

Quick Facts

Tadalafil vs. Other PDE5 Inhibitors — Quick Comparison

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

Understanding tadalafil's mechanism requires understanding the nitric oxide–cGMP signaling cascade that governs smooth muscle tone throughout the body, and particularly in the corpus cavernosum of the penis.

The NO–cGMP–PDE5 Pathway

The physiological process of penile erection begins with sexual stimulation (visual, tactile, or psychological), which triggers parasympathetic nerve signals to the penis. These signals cause the release of nitric oxide (NO) from non-adrenergic non-cholinergic (NANC) nerve terminals and from endothelial cells lining the cavernosal sinusoids (Burnett et al., 1992).

Nitric oxide diffuses into adjacent smooth muscle cells, where it activates the enzyme guanylate cyclase. This enzyme converts guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). Accumulation of cGMP activates protein kinase G (PKG), which phosphorylates multiple downstream targets that collectively reduce intracellular calcium concentration. This causes smooth muscle relaxation in the trabecular tissue and helicine arteries of the corpus cavernosum, allowing blood to fill the cavernosal sinusoids and produce an erection (Corbin & Francis, 1999).

The erection is maintained as long as cGMP concentrations remain elevated. The natural termination of erection occurs when phosphodiesterase type 5 (PDE5) — an enzyme highly expressed in penile smooth muscle — hydrolyzes cGMP back to inactive GMP. This reduces PKG activity, allows intracellular calcium to rise, and restores smooth muscle tone (detumescence).

Where Tadalafil Acts

Tadalafil is a potent, selective, and reversible competitive inhibitor of PDE5. By occupying the catalytic site of PDE5, tadalafil prevents the enzyme from degrading cGMP. The result: when NO is released during sexual stimulation, the cGMP it generates persists longer and reaches higher concentrations than it would in the absence of tadalafil. This amplified cGMP signal produces stronger and more sustained smooth muscle relaxation and penile engorgement (Corbin & Francis, 1999).

Critical point: Tadalafil does not initiate the NO–cGMP cascade. It only amplifies a signal that is already present. Without sexual stimulation and NO release, tadalafil alone will not produce an erection. This is a fundamental difference from injectable prostaglandins (alprostadil), which directly cause smooth muscle relaxation regardless of sexual stimulation.

PDE Selectivity Profile

There are 11 known PDE families (PDE1–PDE11), each with different tissue distributions and substrate specificities. Tadalafil's therapeutic utility and side effect profile are determined by its relative selectivity across these enzymes:

Tadalafil's high selectivity for PDE5 over PDE6 explains why blue-tinted vision (cyanopsia) — a characteristic side effect of sildenafil — is rare with tadalafil. However, its relatively lower selectivity over PDE11A is hypothesized to contribute to the back pain and myalgia that are more commonly reported with tadalafil than with other PDE5 inhibitors, though this remains unproven (Forgue et al., 2006).

Mechanism in Pulmonary Arterial Hypertension

PDE5 is abundantly expressed in pulmonary vascular smooth muscle. In PAH, the pulmonary vasculature undergoes pathological remodeling with vasoconstriction, leading to elevated pulmonary arterial pressure and right heart failure. Tadalafil inhibits PDE5 in the pulmonary vasculature, increasing cGMP levels, promoting vasodilation, and reducing pulmonary vascular resistance. At the 40 mg dose used for PAH (Adcirca), the drug produces sustained reductions in pulmonary arterial pressure over 24 hours (Galiè et al., 2009).

Mechanism in BPH/LUTS

The mechanism by which tadalafil improves lower urinary tract symptoms associated with BPH is multifactorial and not fully elucidated. Proposed mechanisms include:

• Smooth muscle relaxation: PDE5 is expressed in prostate smooth muscle, bladder detrusor muscle, and urethral smooth muscle. Tadalafil-mediated cGMP accumulation relaxes these tissues, reducing urethral resistance and improving urine flow (Oelke et al., 2012).
• Reduced autonomic tone: PDE5 inhibition may modulate afferent nerve signaling from the bladder, reducing overactivity and urgency symptoms.
• Improved pelvic blood flow: Chronic pelvic ischemia has been implicated in BPH/LUTS pathophysiology. Tadalafil-mediated vasodilation may improve pelvic organ perfusion.
• Anti-proliferative effects: Preclinical data suggest that elevated cGMP may inhibit prostate smooth muscle and epithelial cell proliferation, potentially slowing prostate growth.

Pharmacokinetics

The lack of food interaction is a clinically meaningful advantage over sildenafil and vardenafil, both of which have delayed absorption and reduced peak concentrations when taken with high-fat meals. Patients taking tadalafil do not need to coordinate dosing around meals (Forgue et al., 2006).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA-Approved Indications

Erectile Dysfunction

Erectile dysfunction is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects approximately 30 million men in the United States, with prevalence increasing sharply with age (from ~12% at age 40 to ~50% at age 70). ED has both organic (vascular, neurogenic, hormonal) and psychogenic components, and is now recognized as an early marker of cardiovascular disease (Brock et al., 2002).

Tadalafil addresses the vascular component of ED by enhancing the NO–cGMP pathway in the corpus cavernosum. Two dosing strategies are available:

• On-demand (10–20 mg): Taken approximately 30 minutes before anticipated sexual activity. Effective for up to 36 hours after dosing. Starting dose is 10 mg, adjusted to 20 mg or reduced to 5 mg based on efficacy and tolerability. Maximum frequency: once daily.
• Daily (2.5–5 mg): Taken once daily at approximately the same time, regardless of sexual activity. Provides continuous erectile readiness. Starting dose is 2.5 mg, increased to 5 mg if needed. Steady-state levels are reached within 5 days. Preferred by patients who have sexual activity more than twice per week or who prefer spontaneity.

Benign Prostatic Hyperplasia / Lower Urinary Tract Symptoms

BPH affects approximately 50% of men by age 50 and up to 90% by age 80. LUTS associated with BPH include urinary frequency, urgency, nocturia, weak stream, hesitancy, and incomplete emptying. Tadalafil 5 mg daily is FDA-approved for the treatment of the signs and symptoms of BPH, with or without concomitant ED (Oelke et al., 2012).

Tadalafil is the only PDE5 inhibitor approved for BPH/LUTS. In clinical trials, tadalafil 5 mg daily significantly improved International Prostate Symptom Score (IPSS) by approximately 4–5 points compared to a 2–3 point improvement with placebo. Importantly, tadalafil does not reduce prostate size or PSA levels, and it does not address the obstructive component of BPH as effectively as alpha-blockers (tamsulosin) or 5-alpha reductase inhibitors (finasteride). It is most useful in men with mild-to-moderate LUTS who also have ED, as it can address both conditions with a single medication.

Pulmonary Arterial Hypertension

PAH is a progressive disease characterized by elevated pulmonary arterial pressure leading to right heart failure and death. The PHIRST (Pulmonary Arterial Hypertension and Response to Tadalafil) trial demonstrated that tadalafil 40 mg daily significantly improved 6-minute walk distance (the primary endpoint) by 33 meters versus placebo, and reduced the incidence of clinical worsening events. Improvements were seen in WHO functional class and quality of life measures (Galiè et al., 2009).

Under the brand name Adcirca, tadalafil 40 mg is taken once daily for PAH. This dose (double the maximum ED dose) is necessary because the pulmonary vasculature requires sustained, higher-level PDE5 inhibition for therapeutic benefit. Adcirca was originally patent-separated from Cialis, though both contain the identical active ingredient.

Off-Label and Investigational Uses

What Tadalafil Is NOT

• Not an aphrodisiac: Tadalafil does not increase sexual desire, libido, or arousal. It only facilitates the erectile response when sexual stimulation is present. Men with low libido due to hypogonadism, depression, or relationship issues will not experience desire enhancement from tadalafil.
• Not a cure for ED: Tadalafil treats the symptom (insufficient erection) but does not address underlying causes such as atherosclerosis, diabetes-related neuropathy, or hormonal deficiency. It must be taken continuously for ongoing benefit.
• Not a performance enhancer in healthy men: In men with normal erectile function, PDE5 inhibitors produce minimal additional benefit. They do not increase penile size or fundamentally alter sexual performance beyond addressing dysfunction.
• Not a testosterone replacement: Tadalafil does not increase testosterone levels. Men with hypogonadal ED may need testosterone replacement in addition to or instead of PDE5 inhibitors.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

FDA-Approved Dosing

Choosing Between On-Demand and Daily Dosing

Dose Adjustments

Drug Interactions

Administration Tips

• No food restrictions: Unlike sildenafil and vardenafil, tadalafil absorption is not affected by food. It can be taken with meals without loss of efficacy.
• Timing flexibility (on-demand): While labeling says "at least 30 minutes before," some men report efficacy as early as 16 minutes. The extended duration (36 hours) means precise timing is less critical than with shorter-acting PDE5 inhibitors.
• Daily dosing consistency: For daily dosing, take at the same time each day. Some men prefer evening dosing to coincide with bedtime sexual activity; others prefer morning dosing. Either is acceptable.
• Switching from on-demand to daily: When transitioning, start daily dosing without a loading dose. Therapeutic effect builds over 3–5 days as steady-state levels are achieved.
• Tablet splitting: Tadalafil tablets are not scored. Splitting 20 mg tablets for 10 mg doses is commonly done for cost savings but is not officially recommended by the manufacturer. Generic tablets may be available in all standard doses.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What Clinical Trials Show

Erectile Dysfunction — Pivotal Trial Results

Daily Dosing Results

The daily dosing studies demonstrated that tadalafil 5 mg taken once daily produced erectile improvements comparable to on-demand dosing, with the added benefit of "always ready" spontaneity:

• IIEF-EF improvement: +6 to +8 points from baseline with daily 5 mg (vs. +1 to +2 points placebo) (Porst et al., 2006).
• SEP3 success rate: 67–73% with daily 5 mg vs. 31–35% placebo.
• Patient preference: In crossover studies, approximately 73% of men preferred daily dosing over on-demand dosing, citing spontaneity, reduced performance anxiety, and the elimination of planning (Porst et al., 2006).
• Partner satisfaction: Partners of men on daily tadalafil reported significantly higher satisfaction with sexual spontaneity and intimacy quality compared to on-demand use.

BPH/LUTS Results

An important nuance: while tadalafil significantly improves LUTS symptoms (subjective scores), it does not significantly increase maximum urinary flow rate (an objective measure). This suggests that symptom relief may involve sensory nerve modulation and bladder function rather than purely mechanical urethral opening. Patients with severe obstruction requiring surgical intervention will not be adequately treated with tadalafil alone.

PAH Results (PHIRST Trial)

Efficacy in Special Populations

• Diabetes mellitus: Men with diabetes have higher rates of ED and often more severe vascular impairment. Tadalafil remains effective in diabetic men, though response rates are somewhat lower (~56% GAQ improvement with 20 mg vs. 81% in the general ED population). Daily dosing may be particularly beneficial in this population (Goldstein et al., 2003).
• Post-prostatectomy: In men who have undergone nerve-sparing radical prostatectomy, tadalafil can aid erectile recovery. Daily use during the rehabilitation period (starting 1–3 months post-surgery) may support endothelial and nerve recovery in the corpus cavernosum, though results depend on surgical nerve preservation.
• Spinal cord injury: Tadalafil has demonstrated efficacy in men with spinal cord injury and reflexogenic erectile function, improving both erection quality and successful intercourse rates.
• Psychogenic ED: Tadalafil is highly effective in psychogenic ED. The daily dosing option is particularly valued in this population, as it removes the anticipatory anxiety associated with on-demand dosing.

Long-Term Efficacy

Open-label extension studies have demonstrated sustained efficacy of tadalafil over 2+ years of continuous use. Unlike hexarelin and other peptides that develop tachyphylaxis, PDE5 inhibitors do not exhibit receptor desensitization. The same dose remains effective long-term, with no evidence of tolerance development. Discontinuation rates in long-term studies are primarily due to adverse effects (5–8%) or loss of efficacy related to underlying disease progression rather than drug tolerance (Brock et al., 2002).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Common Side Effects (from Phase III Trials)

Data compiled from pooled Phase III clinical trial analyses (Brock et al., 2002; Goldstein et al., 2003).

Back Pain and Myalgia: Tadalafil-Specific Concern

Back pain and myalgia occur more frequently with tadalafil than with other PDE5 inhibitors. These effects are thought to be related to tadalafil's inhibition of PDE11A, which is expressed in skeletal muscle, though this link has not been definitively proven. Key characteristics:

• Typically onset 12–24 hours after dosing (delayed, not acute)
• More common with on-demand 20 mg dosing than daily 5 mg dosing
• Described as a dull, aching quality affecting the lower back and/or limbs
• Self-limiting, resolving within 24–48 hours
• Responsive to NSAIDs (ibuprofen, naproxen) if needed
• More common in the first weeks of use; may diminish with continued use
• Dose-reduction (from 20 mg to 10 mg, or from on-demand to daily 5 mg) often resolves the issue

Serious Adverse Events (Rare)

Cardiovascular Safety

Tadalafil has been extensively studied for cardiovascular safety. Key findings:

• No increased MI or stroke risk: Multiple meta-analyses and post-marketing surveillance studies have found no increased risk of myocardial infarction, stroke, or cardiovascular death with tadalafil use, even in men with established cardiovascular risk factors (Kloner et al., 2003).
• Modest BP reduction: Tadalafil causes a mean reduction of approximately 1–2 mmHg systolic and 0.8 mmHg diastolic in normotensive men. This is not clinically significant in most patients but warrants monitoring in those already on multiple antihypertensives.
• Sexual activity risk: The cardiovascular risk of tadalafil use is primarily the risk of sexual activity itself. Men who can safely perform moderate exercise (climbing 2 flights of stairs, brisk walking) are generally safe to use tadalafil and engage in sexual activity.
• The Princeton Consensus: Guidelines recommend cardiovascular risk stratification before prescribing PDE5 inhibitors. Low-risk patients can safely use them; high-risk patients (unstable angina, uncontrolled hypertension, recent MI/stroke) should defer until stabilized.

Contraindications

• Nitrate medications (ANY form) — Absolute contraindication. Fatal hypotension risk.
• Riociguat (Adempas) — Contraindicated. Synergistic cGMP elevation.
• Hypersensitivity to tadalafil or excipients
• Severe hepatic impairment (Child-Pugh C)
• Recent stroke or MI (within 90 days) — Not an absolute contraindication but requires careful risk assessment
• Unstable angina or angina during sexual intercourse
• Uncontrolled hypertension (>170/100 mmHg)
• Uncontrolled hypotension (<90/50 mmHg)
• Known hereditary retinal degenerative disorders (e.g., retinitis pigmentosa) — PDE6 concerns, though tadalafil's PDE6 inhibition is minimal

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Comparisons: Tadalafil vs. Alternatives

Tadalafil vs. Sildenafil (Viagra)

Sildenafil (Viagra) was the first PDE5 inhibitor (approved 1998) and remains the most widely recognized. It is effective and well-studied, but differs from tadalafil in several clinically meaningful ways:

When to prefer tadalafil over sildenafil: Men who value spontaneity; men who eat before sexual activity; men who want to avoid visual disturbances; men with concomitant BPH/LUTS; men who prefer daily dosing. When to prefer sildenafil: Men who prefer on-demand-only use with shorter systemic exposure; men troubled by back pain/myalgia; men who want a lower-cost option; men for whom a shorter nitrate washout period (24 vs. 48 hours) is clinically relevant.

Tadalafil vs. Vardenafil (Levitra)

Vardenafil (Levitra) was approved in 2003, the same year as tadalafil. It is pharmacologically similar to sildenafil but is rarely the first-choice PDE5 inhibitor today:

• Duration: Similar to sildenafil (4–6 hours), far shorter than tadalafil.
• Onset: Similar to sildenafil (30–60 minutes).
• Food interaction: Yes — high-fat meals reduce absorption.
• QT prolongation: Vardenafil carries a specific warning for QT interval prolongation, making it less suitable for patients on antiarrhythmics (Class IA, Class III) or those with congenital long QT syndrome. Tadalafil does not have this concern.
• Orally disintegrating tablet (ODT): Vardenafil is available as an ODT (Staxyn), which dissolves on the tongue without water. This is its primary differentiating convenience feature.
• Clinical niche: Vardenafil has largely been displaced by tadalafil (duration advantage) and avanafil (faster onset) and does not have generic competition driving prices down as significantly.

Tadalafil vs. Avanafil (Stendra)

Avanafil (Stendra, approved 2012) is the newest PDE5 inhibitor and was designed for rapid onset:

• Onset: 15–30 minutes, the fastest of any PDE5 inhibitor. Some men report efficacy within 15 minutes.
• Duration: 6–12 hours — longer than sildenafil but far shorter than tadalafil's 36 hours.
• Selectivity: The most PDE5-selective of all inhibitors. Minimal PDE6 and PDE11 cross-reactivity. This translates to fewer visual disturbances and less back pain/myalgia.
• Food interaction: Minimal, similar to tadalafil.
• No daily dosing option: On-demand only.
• No generic available: As of 2026, avanafil remains brand-only, making it significantly more expensive than generic tadalafil.
• Best for: Men who want the fastest onset with minimal side effects and are willing to pay a premium. Not suitable for men wanting daily dosing or 36-hour duration.

Tadalafil vs. PT-141 (Bremelanotide / Vyleesi)

PT-141 (bremelanotide) represents a fundamentally different approach to sexual dysfunction. While PDE5 inhibitors like tadalafil work peripherally on blood flow, PT-141 works centrally on sexual desire:

Complementary, not competing: Tadalafil and PT-141 address different dimensions of sexual function. Tadalafil addresses the hydraulic aspect (blood flow to the penis); PT-141 addresses the desire aspect (central arousal). A man with both low desire and vascular ED might theoretically benefit from both, though this combination is not formally studied or FDA-approved. PT-141 is FDA-approved only for premenopausal women with HSDD; any use in men is off-label (Diamond et al., 2004).

Comprehensive Comparison Matrix

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

Pivotal Clinical Trials

Cardiovascular Research

PDE5 is expressed in the myocardium, and the cGMP-PKG pathway plays important roles in cardiac physiology. This has prompted significant investigation of tadalafil in cardiovascular disease:

• RELAX trial (HFpEF): A large, NIH-funded randomized trial tested tadalafil 20 mg daily in heart failure with preserved ejection fraction. Unfortunately, the primary endpoint (peak oxygen consumption) was not met. Tadalafil did not improve exercise capacity or clinical status in HFpEF. This was a notable negative result that tempered enthusiasm for PDE5 inhibitors in this disease (Redfield et al., 2013).
• Right heart failure in PAH: Beyond the PHIRST trial, ongoing research examines the long-term effects of tadalafil on right ventricular remodeling in PAH. Early data suggest that PDE5 inhibition may slow RV hypertrophy and improve RV function, potentially extending beyond hemodynamic effects to direct myocardial benefit.
• Cardiac surgery / ischemia-reperfusion: Preclinical studies show that PDE5 inhibition provides cardioprotection against ischemia-reperfusion injury through cGMP-PKG-dependent opening of mitochondrial K_ATP channels. Human studies are limited but ongoing.
• Endothelial function: Tadalafil improves flow-mediated dilation (FMD) — a measure of endothelial function — in multiple studies. This has implications for cardiovascular risk reduction beyond its immediate hemodynamic effects.

Duchenne Muscular Dystrophy

The absence of dystrophin in DMD leads to loss of neuronal nitric oxide synthase (nNOS) from the sarcolemma, resulting in impaired NO-cGMP signaling in skeletal and cardiac muscle. PDE5 inhibition was hypothesized to compensate by amplifying whatever residual cGMP signaling remains:

• Preclinical studies in mdx mice (DMD model) showed that tadalafil improved blood flow to exercising muscle, reduced exercise-induced ischemia, and improved muscle function.
• Early human studies showed improved blood flow responses during exercise in DMD boys treated with tadalafil.
• However, larger clinical trials have produced mixed results, and tadalafil is not currently approved for DMD. Research continues with focus on cardiac outcomes and longer-term muscle function.

Penile Rehabilitation

Following radical prostatectomy, cavernous nerve injury leads to neuropraxia and potential structural changes in the corpus cavernosum (smooth muscle atrophy, fibrosis). The concept of "penile rehabilitation" proposes that regular PDE5 inhibitor use during the nerve recovery period preserves cavernosal tissue and improves eventual erectile recovery:

• Rationale: Tadalafil maintains cavernosal oxygenation through regular partial erections and may have direct anti-fibrotic effects via cGMP signaling in cavernosal smooth muscle.
• Evidence: Multiple studies have evaluated daily tadalafil 5 mg for penile rehabilitation. Results are mixed: some show improved early erectile recovery and reduced penile length loss; others show no significant difference vs. placebo at 12–24 months. The REACTT trial (Recovery of Erections: Intervention with Tadalafil) showed that daily tadalafil 5 mg significantly improved unassisted erection rates at 9 months compared to on-demand tadalafil or placebo (Montorsi et al., 2014).
• Current practice: Many urologists prescribe daily tadalafil post-prostatectomy despite mixed evidence, reasoning that the favorable safety profile and potential benefit justify the approach. It remains an area of active research.

Female Sexual Dysfunction

PDE5 is expressed in clitoral, vaginal, and labial smooth muscle, suggesting that PDE5 inhibitors could enhance genital blood flow and arousal in women. Several trials have evaluated tadalafil in women:

• Results have been inconsistent, with some studies showing improved genital sensations and arousal but no consistent benefit on overall sexual satisfaction scores.
• The complexity of female sexual response — involving desire, arousal, orgasm, and satisfaction components — means that addressing the vascular component alone is often insufficient.
• Tadalafil is not FDA-approved for any indication in women. PT-141 (bremelanotide/Vyleesi), which targets central desire pathways, has been approved for hypoactive sexual desire disorder in premenopausal women.

Altitude Medicine

Tadalafil has been studied for prevention of high-altitude pulmonary edema (HAPE). By reducing pulmonary vascular resistance at altitude, tadalafil may prevent the pathological pulmonary hypertension that leads to HAPE:

• A randomized controlled trial by Maggiorini et al. (2004) demonstrated that tadalafil 10 mg twice daily significantly reduced the incidence of HAPE during rapid ascent to 4,559 meters (Maggiorini et al., 2004).
• Tadalafil's long half-life makes it more convenient than sildenafil (which requires TID dosing) for altitude prophylaxis.
• Some altitude medicine specialists include tadalafil in their HAPE prevention recommendations, though it is not FDA-approved for this indication.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Approval Timeline

Prescription Status

Tadalafil is a prescription-only medication in the United States and most countries. It is not a controlled substance (no DEA scheduling). This means:

• A valid prescription from a licensed provider (physician, NP, PA) is required
• It can be prescribed in standard quantities without DEA registration requirements
• Refills are managed by the prescriber without controlled substance limitations
• Telemedicine prescribing is permitted in most states for ED medications, making remote consultation and prescription increasingly common

Patent History and Generic Availability

The patent and exclusivity history of tadalafil is complex but clinically relevant because of its impact on cost:

• Original patents: ICOS Corporation held the original compound patent. Eli Lilly partnered on development and marketing.
• Patent expiration: The primary US patent expired in September 2018. Several legal challenges and settlement agreements shaped the exact timeline.
• Generic entry: Multiple generic manufacturers (including Teva, Mylan/Viatris, Aurobindo, Camber, and others) launched generic tadalafil in 2018, rapidly driving prices down.
• Impact: The average retail price of tadalafil dropped from approximately $30–$50 per tablet (brand Cialis) to $0.30–$3 per tablet (generic) within months of generic entry, transforming accessibility.

International Regulatory Status

OTC / Non-Prescription Trends

There is a global trend toward increasing non-prescription access to PDE5 inhibitors for ED. In the UK, sildenafil 50 mg (Viagra Connect) became available over-the-counter in pharmacies in 2018. Similar reclassification discussions have occurred for tadalafil. In the United States, no PDE5 inhibitor is currently available OTC, but telemedicine platforms have significantly reduced barriers to obtaining prescriptions. Whether tadalafil will eventually be available OTC in the US remains uncertain, but the trajectory in other countries suggests it is plausible.

Online Prescribing and Telemedicine

Tadalafil is one of the most commonly prescribed medications through telemedicine platforms (Hims, Ro, Lemonaid, etc.). These services typically offer:

• Asynchronous or live video consultation with a licensed provider
• Prescription issuance based on health questionnaire and medical history
• Direct-to-patient pharmacy delivery
• Competitive pricing (often $1–$3 per dose for generic tadalafil)

While convenient, telemedicine prescribing has limitations: physical examination is not performed, cardiovascular risk stratification may be incomplete, and drug interaction screening relies on patient-reported medication lists. The American Urological Association recommends that a comprehensive evaluation (including cardiovascular risk assessment) be performed before initiating PDE5 inhibitor therapy.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Pricing Overview

Monthly Cost by Dosing Strategy

Insurance Coverage

Insurance coverage for tadalafil is variable and indication-dependent:

• ED indication: Many commercial insurance plans cover generic tadalafil for ED but with quantity limits (typically 6–12 tablets per month). Prior authorization may be required. Some plans exclude ED medications entirely. Medicare Part D plans generally do not cover ED medications (excluded by statute).
• BPH/LUTS indication: When prescribed for BPH (with appropriate ICD-10 coding), insurance coverage is generally more robust because BPH is not subject to the same coverage exclusions as ED. Daily 5 mg tadalafil coded for BPH may be covered even when ED-coded tadalafil is not.
• PAH indication (Adcirca): Generally covered by insurance and specialty pharmacy benefit for PAH diagnosis. Prior authorization and documentation of PAH severity typically required. Patient assistance programs are available from the manufacturer.
• Cost-saving strategies: GoodRx and similar discount programs can reduce generic tadalafil prices to $9–$25 for 30 tablets. Splitting 20 mg tablets (not scored, but commonly done) can reduce per-dose costs. Manufacturer coupons are available for brand Cialis but savings are modest.

Cost Comparison: Tadalafil vs. Alternatives

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Q: How long does tadalafil really last?

Answer: Tadalafil's therapeutic window extends up to 36 hours after a single on-demand dose (10–20 mg). This is based on clinical trial data showing that men could achieve successful intercourse as late as 36 hours post-dose at rates significantly above placebo (Porst et al., 2003). The 36-hour figure is the outer limit — most men report strongest effects in the first 12–24 hours. With daily 5 mg dosing, the drug reaches steady-state within 5 days, and the therapeutic effect is continuous (no "window" to worry about). The long duration is due to tadalafil's 17.5-hour half-life, which means that even 36 hours after dosing, approximately 25% of the peak plasma concentration remains — enough for clinical effect in many men.

Q: Can I take tadalafil with blood pressure medication?

Answer: In most cases, yes, but with important caveats. Tadalafil produces a modest blood pressure reduction (1–2 mmHg systolic on average). Most antihypertensives are compatible with tadalafil, and the additive effect is generally clinically insignificant. However, there are two critical exceptions: (1) Nitrates are ABSOLUTELY CONTRAINDICATED — the combination causes severe, potentially fatal hypotension. This includes nitroglycerin (sublingual, patch, spray), isosorbide mononitrate, isosorbide dinitrate, and recreational amyl nitrite/butyl nitrite ("poppers"). (2) Alpha-blockers (doxazosin, prazosin, terazosin, tamsulosin) require careful co-administration because of additive hypotension risk, particularly orthostatic hypotension. Start tadalafil at the lowest dose when combining with alpha-blockers, and ensure the patient is hemodynamically stable on the alpha-blocker first (Kloner et al., 2003). Always inform your prescriber of all blood pressure medications.

Q: Does tadalafil increase sex drive (libido)?

Answer: No. Tadalafil works on blood flow to the penis — it facilitates the physical mechanism of erection when sexual stimulation is present. It does not affect desire, arousal, or libido, which are mediated by hormonal (testosterone) and central nervous system (dopamine, melanocortin) pathways that PDE5 inhibitors do not target. If low sex drive is the primary concern, evaluation for hypogonadism (low testosterone) is warranted before or alongside PDE5 inhibitor therapy. For desire-specific treatment, PT-141 (bremelanotide), which acts on melanocortin-4 receptors in the brain, addresses the desire component but is currently FDA-approved only for women with HSDD (Diamond et al., 2004).

Q: Is daily tadalafil better than on-demand?

Answer: It depends on your situation. Daily dosing advantages: continuous readiness (no planning needed), eliminates performance anxiety around timing, addresses BPH/LUTS simultaneously, generally fewer side effects (lower peak plasma levels), preferred by ~73% of men in crossover studies. On-demand advantages: lower cost if sexual activity is infrequent, less total drug exposure over time, suitable for men who prefer medication only when needed. Clinical recommendation: Daily dosing is generally preferred for men with frequent sexual activity (≥2x/week), coexisting BPH, or significant performance anxiety. On-demand is reasonable for men with occasional sexual activity or those who prefer minimal medication use (Porst et al., 2006).

Q: Can I take tadalafil with alcohol?

Answer: Moderate alcohol (1–2 drinks) is generally acceptable with tadalafil. However, alcohol is itself a vasodilator, and combining it with tadalafil increases the risk of dizziness, lightheadedness, and orthostatic hypotension (drop in blood pressure upon standing). Heavy alcohol use is strongly discouraged because: (1) it amplifies hypotensive effects; (2) alcohol itself impairs erectile function through CNS depression, neuropathy, and hormonal disruption; and (3) the combination increases headache risk. The pharmacokinetic interaction is minimal (alcohol does not significantly alter tadalafil metabolism), but the pharmacodynamic interaction (additive vasodilation) is clinically relevant at high alcohol intake.

Q: Will tadalafil work if I have diabetes?

Answer: Yes, though response rates are somewhat lower. In clinical trials, approximately 56% of diabetic men on tadalafil 20 mg reported improved erections, compared to 81% in the general ED population (Goldstein et al., 2003). The lower response rate reflects the multifactorial nature of diabetic ED (neuropathy, endothelial dysfunction, microvascular disease). Daily dosing (5 mg) may be particularly beneficial in diabetic men by providing continuous vascular support. Optimizing diabetes control (HbA1c, blood pressure, lipids) improves response to PDE5 inhibitors. Some diabetic men with severe vascular and neurogenic damage may not respond adequately to any PDE5 inhibitor and may require alternative treatments (intracavernosal injections, vacuum devices, or penile prosthesis).

Q: Can women take tadalafil?

Answer: Tadalafil is not FDA-approved for any indication in women. PDE5 is expressed in female genital tissue (clitoris, vaginal wall), and some studies have explored tadalafil for female sexual arousal disorder with mixed results. Tadalafil may modestly improve genital blood flow and physical arousal sensations in some women, but it has not consistently improved overall sexual satisfaction in clinical trials. The complexity of female sexual response means that a vascular-only intervention is rarely sufficient. Women seeking treatment for sexual dysfunction should consult a specialist who can evaluate desire, arousal, orgasm, and pain components individually. Tadalafil 40 mg (as Adcirca) is approved for PAH in both men and women.

Q: What if tadalafil doesn't work for me?

Answer: Before concluding that tadalafil has failed, ensure it has been used correctly: (1) adequate sexual stimulation must be present; (2) on-demand doses should be tried at least 4–6 times before declaring failure (some men need multiple attempts to find optimal timing and dose); (3) the maximum dose (20 mg on-demand or 5 mg daily) should be tried; (4) food and alcohol interactions should be minimized. If tadalafil is genuinely ineffective, options include: trying an alternative PDE5 inhibitor (some men respond better to sildenafil or avanafil); evaluating for underlying conditions (severe arterial insufficiency, venous leak, hormonal deficiency); intracavernosal injection therapy (alprostadil, trimix); vacuum erection devices; or surgical options (penile prosthesis) for severe, refractory ED. Approximately 30–40% of men with organic ED do not respond adequately to any PDE5 inhibitor.

Q: Is tadalafil safe for the heart?

Answer: Tadalafil has an excellent cardiovascular safety record. Multiple large-scale analyses have shown no increased risk of heart attack, stroke, or cardiovascular death with tadalafil use (Kloner et al., 2003). In fact, PDE5 inhibitors have potential cardioprotective properties through improved endothelial function and reduced left ventricular stiffness. The critical safety issue is the contraindication with nitrate medications, which can cause fatal hypotension. The cardiac risk associated with tadalafil is primarily the risk of the sexual activity it enables, not the drug itself. Men who can perform moderate physical exertion (walking briskly, climbing two flights of stairs) without cardiac symptoms are generally safe to use tadalafil and engage in sexual activity.

Q: Does long-term tadalafil use cause dependence or tolerance?

Answer: No. Tadalafil does not cause physical dependence, psychological addiction, or pharmacological tolerance. PDE5 inhibitors do not desensitize their target enzyme — the same dose remains effective long-term with no evidence of tachyphylaxis in studies extending over 2+ years. Tadalafil is not a controlled substance and has no abuse potential. If ED worsens over time while on tadalafil, this typically reflects progression of the underlying vascular disease (atherosclerosis, diabetes progression), not drug tolerance. Some men report a psychological component — feeling they "need" the pill for confidence — but this is performance anxiety, not pharmacological dependence.

Q: What about "poppers" (amyl nitrite)?

Answer: Absolutely do not combine tadalafil with poppers. Amyl nitrite and butyl nitrite ("poppers") are recreational vasodilating inhalants that are pharmacologically nitrates. The same contraindication that applies to prescription nitrates applies to poppers: the combination with any PDE5 inhibitor causes severe, potentially fatal hypotension. This risk is particularly dangerous because tadalafil's long half-life (17.5 hours) means the drug is active for up to 36 hours after dosing — a man who takes tadalafil Friday evening is still at risk if he uses poppers Saturday night. Multiple deaths have been attributed to this combination. There is no safe way to combine poppers with tadalafil.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on over two decades of clinical use, robust Phase III trial data, and extensive post-marketing surveillance:

• Tadalafil is the longest-acting PDE5 inhibitor. Its 17.5-hour half-life provides a therapeutic window of up to 36 hours — earning it the nickname "the weekend pill." This duration is unmatched by sildenafil (4–6 hours), vardenafil (4–6 hours), or avanafil (6–12 hours).
• It is the only PDE5 inhibitor with a daily dosing option. Tadalafil 2.5–5 mg daily provides continuous erectile readiness without timing constraints. Approximately 73% of men in crossover studies preferred daily over on-demand dosing.
• Three FDA-approved indications. Tadalafil is approved for ED (Cialis), BPH/LUTS (Cialis), and PAH (Adcirca). It is the most versatile PDE5 inhibitor and can treat both ED and BPH simultaneously with a single daily 5 mg tablet.
• Food does not affect absorption. Unlike sildenafil and vardenafil, tadalafil can be taken with or without food, including high-fat meals. This is a practical convenience advantage.
• Generic availability since 2018 has dramatically reduced cost. Monthly costs for daily generic tadalafil range from $9–$30, compared to $400–$500 for brand Cialis. This has transformed accessibility.
• Nitrate co-administration is ABSOLUTELY CONTRAINDICATED. This is the most critical safety consideration. Combined use with any nitrate medication or recreational "poppers" can cause fatal hypotension. Due to tadalafil's long half-life, a 48-hour washout period is required (longer than the 24-hour requirement for shorter-acting PDE5 inhibitors).
• Side effects are generally mild and manageable. Headache (15%), dyspepsia (10%), back pain (6%), and myalgia (5%) are the most common. Back pain/myalgia are more common with tadalafil than with other PDE5 inhibitors, possibly related to PDE11 inhibition. Serious adverse events (priapism, NAION, sudden hearing loss) are extremely rare.
• Cardiovascular safety is well-established. No increased risk of MI, stroke, or cardiovascular death. The main risk is the sexual activity itself, not the medication.
• It does NOT increase libido, desire, or arousal. Tadalafil facilitates the physical mechanism of erection when sexual stimulation is present. It does not cause spontaneous erections or increase sex drive.
• No tolerance or dependence. PDE5 inhibitors do not desensitize. The same dose remains effective long-term with no evidence of pharmacological tolerance.
• Effective across ED etiologies and populations. Including psychogenic ED, diabetic ED, post-prostatectomy ED, and spinal cord injury. Response rates are highest in psychogenic and mild vascular ED; lower in severe diabetic and post-surgical populations.

Who Should Consider Tadalafil

• Men with erectile dysfunction who want long duration of action or daily dosing
• Men with both ED and BPH/LUTS (single medication addresses both)
• Men who want to take an ED medication without timing it around meals
• Men with performance anxiety who benefit from "always being ready" (daily dosing)
• Patients with PAH requiring oral pulmonary vasodilator therapy
• Men who have tried sildenafil and experienced bothersome visual disturbances
• Those seeking an affordable, well-studied, generic ED treatment

Who Should NOT Take Tadalafil

• Anyone taking nitrate medications in any form (nitroglycerin, isosorbide, poppers)
• Anyone taking riociguat (Adempas)
• Men with severe hepatic impairment (Child-Pugh C)
• Men with recent MI or stroke (within 90 days without cardiology clearance)
• Men with unstable angina or angina during intercourse
• Men with uncontrolled hypertension or symptomatic hypotension
• Anyone with known hypersensitivity to tadalafil

Questions to Ask Your Doctor

• Is my ED likely vascular, neurogenic, hormonal, or psychogenic — and how does that affect treatment choice?
• Should I use on-demand or daily tadalafil based on my sexual activity pattern?
• Do any of my current medications interact with tadalafil (especially nitrates, alpha-blockers)?
• Should I get a cardiovascular evaluation before starting tadalafil?
• Could my ED be a sign of underlying cardiovascular disease that needs investigation?
• Do I also have BPH/LUTS symptoms that daily tadalafil could address?
• Should I check testosterone levels, given my symptoms?
• What are my options if tadalafil doesn't work sufficiently?

Sources & Further Reading

Foundational Pharmacology

• Corbin JD, Francis SH. (1999) — "Pharmacology of phosphodiesterase-5 inhibitors." International Journal of Clinical Practice, 53(4):303-308. Comprehensive review of PDE5 enzyme biology and inhibitor pharmacology.
• Burnett AL, Lowenstein CJ, Bredt DS, et al. (1992) — "Nitric oxide: a physiologic mediator of penile erection." Science, 257(5068):401-403. Landmark paper establishing the role of NO in erectile physiology.
• Forgue ST, Patterson BE, Bedding AW, et al. (2006) — "Tadalafil pharmacokinetics in healthy subjects." British Journal of Clinical Pharmacology, 61(3):280-288. Comprehensive PK characterization including half-life, metabolism, food effects, and dose proportionality.

Erectile Dysfunction Clinical Trials

• Brock GB, McMahon CG, Chen KK, et al. (2002) — "Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses." Journal of Urology, 168(4 Pt 1):1332-1336. Pooled Phase III efficacy and safety data from pivotal ED trials.
• Porst H, Padma-Nathan H, Giuliano F, et al. (2003) — "Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing." Urology, 62(1):121-125. Landmark study establishing the 36-hour efficacy window.
• Porst H, Giuliano F, Glina S, et al. (2006) — "Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction." European Urology, 50(2):351-359. Key daily dosing efficacy trial.
• Goldstein I, Young JM, Fischer J, et al. (2003) — "Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes." Diabetes Care, 26(3):777-783. ED efficacy in diabetic populations (comparator data).

BPH / LUTS

• Oelke M, Giuliano F, Mirone V, et al. (2012) — "Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial." European Urology, 61(5):917-925. Pivotal BPH/LUTS trial comparing tadalafil to tamsulosin and placebo.

Pulmonary Arterial Hypertension

• Galiè N, Brundage BH, Ghofrani HA, et al. (2009) — "Tadalafil therapy for pulmonary arterial hypertension." Circulation, 119(22):2894-2903. PHIRST trial — pivotal Phase III PAH trial establishing tadalafil efficacy.

Cardiovascular Safety & Drug Interactions

• Kloner RA, Mitchell M, Emmick JT. (2003) — "Cardiovascular effects of tadalafil." American Journal of Cardiology, 92(9 Suppl):37M-46M. Comprehensive cardiovascular safety review including nitrate interaction data.
• McGwin G Jr, Vaphiades MS, Hall TA, Owsley C. (2006) — "Non-arteritic anterior ischemic optic neuropathy and the treatment of erectile dysfunction." British Journal of Ophthalmology, 90(2):154-157. NAION risk evaluation with PDE5 inhibitors.

Penile Rehabilitation & Post-Prostatectomy

• Montorsi F, Brock G, Stolzenburg JU, et al. (2014) — "Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT)." European Urology, 65(3):587-596. Landmark penile rehabilitation trial with daily tadalafil.

Heart Failure Research

• Redfield MM, Chen HH, Borlaug BA, et al. (2013) — "Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial (RELAX)." JAMA, 309(12):1268-1277. Notable negative trial of tadalafil in HFpEF.

Altitude Medicine

• Maggiorini M, Brunner-La Rocca HP, Peth S, et al. (2004) — "Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema." Annals of Internal Medicine, 145(7):497-506. Randomized trial of tadalafil for HAPE prevention.

PT-141 / Bremelanotide Comparison

• Diamond LE, Earle DC, Heiman JR, et al. (2004) — "Bremelanotide (PT-141): a melanocortin agonist for the treatment of sexual dysfunction." Annals of the New York Academy of Sciences, 994:361-371. Characterization of PT-141 mechanism and early efficacy data.

Regulatory & Labeling

• FDA: Cialis (tadalafil) Full Prescribing Information (2018 label revision)
• FDA: Adcirca (tadalafil) Full Prescribing Information

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.